RELATED PARTY TRANSACTIONS	6 Months Ended
Jun. 30, 2022
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	16. RELATED PARTY TRANSACTIONS On March 8, 2021, we entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which we agreed to issue and sell 25,000 shares of our PIPE Shares for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million. This agreement closed and the shares were sold and issued for $25.0 million on November 19, 2021. The Chairman of our board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor. In connection with our acquisition of Novitium, we entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam and Chad Gassert. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company’s board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (“Scitus”), which provides clinical research services to Novitium, majority interest in SS Pharma LLC (“SS Pharma”), which acquires and supplies API to Novitium, majority interest in Esjay Pharma LLC (“Esjay”), which provides research and development and facilities consulting services, and a minority interest in Nuray Chemical Private Limited (“Nuray”), which manufactures and supplies API to Novitium. Mr. Gassert holds a minority interest in Scitus. During the three months ended June 30, 2022, we paid Esjay an immaterial amount, paid SS Pharma $0.7 million, and paid Scitus $0.7 million. During the three months ended June 30, 2022, there were no payments to Nuray. During the six months ended June 30, 2022, we paid Esjay $0.1 million, paid SS Pharma $1.6 million, paid Nuray $0.9 million, and paid Scitus $1.3 million. As of June 30, 2022, the outstanding balance due to Scitus was $50 thousand and the outstanding balance due to SS Pharma was $0.6 million. As of June 30, 2022, there were no outstanding balances due to Esjay and Nuray.

RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2022

16. RELATED PARTY TRANSACTIONS

On March 8, 2021, we entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which we agreed to issue and sell 25,000 shares of our PIPE Shares for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million. This agreement closed and the shares were sold and issued for $25.0 million on November 19, 2021. The Chairman of our board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor.

In connection with our acquisition of Novitium, we entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam and Chad Gassert. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company’s board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (“Scitus”), which provides clinical research services to Novitium, majority interest in SS Pharma LLC (“SS Pharma”), which acquires and supplies API to Novitium, majority interest in Esjay Pharma LLC (“Esjay”), which provides research and development and facilities consulting services, and a minority interest in Nuray Chemical Private Limited (“Nuray”), which manufactures and supplies API to Novitium. Mr. Gassert holds a minority interest in Scitus. During the three months ended June 30, 2022, we paid Esjay an immaterial amount, paid SS Pharma $0.7 million, and paid Scitus $0.7 million. During the three months ended June 30, 2022, there were no payments to Nuray. During the six months ended June 30, 2022, we paid Esjay $0.1 million, paid SS Pharma $1.6 million, paid Nuray $0.9 million, and paid Scitus $1.3 million. As of June 30, 2022, the outstanding balance due to Scitus was $50 thousand and the outstanding balance due to SS Pharma was $0.6 million. As of June 30, 2022, there were no outstanding balances due to Esjay and Nuray.